ArticleCancer science2013

Phase I trial of OTS11101, an anti-angiogenic vaccine targeting vascular endothelial growth factor receptor 1 in solid tumor.

Hidetoshi Hayashi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.